Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$210 Mln
P/E Ratio
--
P/B Ratio
0.61
Industry P/E
--
Debt to Equity
0
ROE
-0.3 %
ROCE
-29.46 %
Div. Yield
0 %
Book Value
4.32
EPS
-1.11
CFO
$-272.77 Mln
EBITDA
$-337.05 Mln
Net Profit
$-327.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| -49.55 | -16.57 | -37.19 | -38.71 | 7.98 | -- | -- |
|
BSE Sensex
| 1.72 | 3.50 | 4.95 | 8.90 | 11.18 | 21.04 | 11.14 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Terns Pharmaceuticals (TERN)
| -14.53 | -36.25 | 43.99 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.31 | 9,973.38 | 20.56 | 23.13 | |
| 279.03 | 8,956.07 | 23.48 | 58.42 | |
| 25.58 | 9,559.25 | -- | -28.77 | |
| 101.91 | 10,030.35 | 30.81 | 14.16 |
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that... is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Address: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404 Read more
President & Head of Research & Development
Dr. Erin Quirk M.D.
President & Head of Research & Development
Dr. Erin Quirk M.D.
Headquarters
Foster City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Terns Pharmaceuticals Inc (TERN) stood at $ 364 Mln as on 31-Dec-24
The share price of Terns Pharmaceuticals Inc (TERN) is $2.80 (NASDAQ) as of 22-Apr-2025 14:38 EDT. Terns Pharmaceuticals Inc (TERN) has given a return of 7.98% in the last 3 years.
Terns Pharmaceuticals Inc (TERN) has a market capitalisation of $ 210 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Terns Pharmaceuticals Inc (TERN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Terns Pharmaceuticals Inc (TERN) and enter the required number of quantities and click on buy to purchase the shares of Terns Pharmaceuticals Inc (TERN).
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Address: 1065 East Hillsdale Boulevard, Foster City, CA, United States, 94404
The CEO & director of Dr. Erin Quirk M.D.. is Terns Pharmaceuticals Inc (TERN), and CFO & Sr. VP is Dr. Erin Quirk M.D..
There is no promoter pledging in Terns Pharmaceuticals Inc (TERN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Terns Pharmaceuticals Inc. (TERN) | Ratios |
|---|---|
|
Return on equity(%)
|
-29.56
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Terns Pharmaceuticals Inc (TERN) was $0 Mln.
$0.09
(
